SEOUL, South Korea and NEW YORK, June 20, 2025 /PRNewswire/ — Parataxis Holdings LLC (“Parataxis Holdings”), an affiliate of Parataxis Capital Administration LLC (“Parataxis Capital” or “PCM”), by means of Parataxis Korea Fund I LLC and associates, has entered right into a definitive settlement with Bridge Biotherapeutics, Inc. (“Bridge Bio” or the “Firm”) to take a position KRW 25 billion which would offer Parataxis Holdings a controlling curiosity within the Firm (the “Transaction”). Following the closing of the Transaction, the Firm intends to alter its company title to Parataxis Korea and stay listed on the KOSDAQ. The Transaction is topic to customary closing circumstances, together with approval by the Firm’s shareholders.
The Transaction would end result within the creation of a Bitcoin-native treasury platform within the South Korean public markets that’s anchored by institutional buyers with important expertise in digital asset investments. As a part of the Transaction, Edward Chin, Founder and CEO of Parataxis Holdings, and Co-Founder & CEO of Parataxis Capital, can be becoming a member of the Board of Administrators of the Firm. Andrew Kim, Associate at Parataxis Capital, will assume the position of CEO of the Firm and also will be part of the Board of Administrators. James Jungkue Lee, Co-founder of Bridge Bio will proceed to steer the core biotech enterprise and serve on the Firm’s Board of Administrators.
“Impressed by the rising curiosity in BTC treasury methods seen in firms like Technique within the US and Metaplanet in Japan, we imagine institutional curiosity on this house is growing globally. We see South Korea as an necessary market within the evolution of BTC adoption. Our intent is to help institutional entry to BTC publicity whereas emphasizing sound company governance and disciplined capital administration,” stated Andrew Kim.
“We’re extremely excited to create the primary BTC treasury firm in South Korea backed by an institutional-grade platform. Given the strategic nature of BTC on the worldwide stage and its finite provide, we imagine that constructing and rising an organization like Parataxis Korea and accumulating a BTC treasury will profit our shareholders in addition to the nation over the long term,” stated Edward Chin of Parataxis Holdings.
Together with the contemplated Transaction, Parataxis Holdings is closing one other fund with considerably the identical technique, and is within the strategy of launching extra fund automobiles.
Parataxis Holdings expects to announce extra particulars relating to the Transaction after conducting a shareholder assembly anticipated in August. Shin & Kim LLC, is performing as authorized advisor to Parataxis Korea Fund I LLC within the Transaction. Deloitte is performing as monetary advisor to Parataxis Korea Fund I LLC within the Transaction.
About Parataxis Capital Administration and Parataxis Holdings
Parataxis Capital Administration is a multi-strategy funding agency centered on the digital asset sector. PCM was based in 2019 and manages a number of commingled hedge fund automobiles and gives sub-advisory companies for institutional allocators, household places of work, fund-of-funds and high-net price people. Parataxis Holdings is an affiliate of PCM and centered on BTC treasury and different digital asset funding alternatives. Each companies are headquartered in New York Metropolis.
About Bridge Biotherapeutics
Bridge Biotherapeutics, Inc. is a medical stage biotech firm engaged within the growth and commercialization of therapeutics for the therapy of ulcerative colitis, fibrotic illnesses, and cancers worldwide. The Firm was based in 2015 and was listed on the KOSDAQ in 2019. Bridge Bio is headquartered in Seongnam, South Korea.
Ahead-Trying Statements:
This press launch incorporates forward-looking statements, together with however not restricted to these referring to the proposed transaction, potential enterprise mixture, and the anticipated use of proceeds. These statements are based mostly on present expectations and projections and are topic to dangers and uncertainties that would trigger precise outcomes to vary materially. There isn’t a assurance that the transaction described herein can be accomplished as contemplated, or in any respect. The Firm assumes no obligation to revise or replace any forward-looking statements after the date of this launch, besides as required by relevant legislation.
This press launch doesn’t represent a suggestion to promote or a solicitation of a suggestion to purchase any securities in any jurisdiction, and shouldn’t be interpreted as funding recommendation or a suggestion relating to any funding determination. Investing entails inherent dangers, together with the potential lack of principal. Any funding determination should be made solely on the discretion and duty of the investor. No illustration or guarantee, categorical or implied, is made by the Firm with respect to the accuracy of any info contained herein or the achievement of any funding returns or monetary outcomes.
Media Contacts:
Parataxis: [email protected]
Bridge Bio: [email protected]
KPR: [email protected]